Get AUVI-Q for $0 out-of-pocket

Eligibility details
Sign up to receive updates Prescribe AUVI-Q in 3 easy steps Watch our videos

How to e-Prescribe AUVI-Q

If you’ve decided AUVI-Q is right for your commercially insured patients, getting it to them is easy through the direct delivery service. Prescribe AUVI-Q, then follow these three simple steps.

  1. Select ASPN
    (mail order pharmacy)
    in EMR
  2. In the EMR notes section, be sure to add medical history including:
    • specific life-threatening allergies
    • patient weight
    • any other safety issues that
      support the prescribed dose
  3. Send prescription
    and have your patient
    connect with ASPN by
    calling 1-844-357-3968

ASPN Pharmacies receives the e-Prescription and follows up with your office, as needed, to obtain missing information.

You can contact our support staff, if needed, for assistance in the enrollment process by calling 1-877-30-AUVIQ.

If you don’t have an EMR system, complete the enrollment form and fax it to 1-877-397-7479

Download the enrollment form

Each prescription pack comes with 2 AUVI-Q auto-injectors and a trainer.19

When you prescribe through the direct delivery service, the out-of-pocket cost for your commercially insured patient is no cost at all.

Those with commercial insurance, including those with high-deductible plans, pay $0 out of pocket* when they obtain AUVI-Q through the direct delivery service.
*Please see full terms and conditions.

Those without government or commercial insurance who cannot afford their medicines may be eligible for support through the kaléo Cares Program.

To be eligible for $0 out of pocket, commercially insured patients must be prescribed AUVI-Q through the direct delivery service, done either in your EMR system or by faxing in the completed enrollment form.

We continually strive to manufacture AUVI-Q with the highest standards in safety, precision, and consistent quality.

AUVI-Q is manufactured on an intelligent, high-tech, 100% automated robotic production line with over 100 automated quality checks on each AUVI-Q device, ensuring a streamlined and consistent production process. The automated robotic production line helps produce a consistent, high-quality product.

The AUVI-Q manufacturing process uses specially calibrated sensors and vision inspection systems to help ensure each component is assembled into AUVI-Q with precision. Every component built into each AUVI-Q has an identifier and is tracked throughout the manufacturing process.

Making AUVI-Q

Designed with size in mind.

About the size of a credit card and thickness of a cell phone, AUVI-Q fits in most pockets, small purses, and diaper bags.

Get to know the AUVI-Q voice.

AUVI-Q contains an electronic voice instruction system to help guide users through the entire epinephrine injection.11

A 2-second countdown begins after AUVI-Q is activated. Voice instructions will indicate the injection is complete, AUVI-Q will beep, and the lights will blink red. After use, seek immediate medical attention.11

A closer look at the first and only EAI with an automatic needle retraction system.

The AUVI-Q auto-retractable needle is not visible before, during, or after injection, and completes epinephrine injection in seconds.

Epinephrine injection is complete in less than half a second. However, users must push firmly and hold for a complete 2-second count.

To minimize the risk of injection-related injury, when administering AUVI-Q to young children and infants, the prescribing information instructs caregivers to hold the child's leg firmly in place and limit movement prior to and during injection.19

Before

During

After

patient leg

Developed by Patients, for Patients®.

AUVI-Q was developed by twin brothers who grew up with life-threatening allergies, and was designed using Human Factors Engineering. Human Factors Engineering places the patient and caregiver at the center of the development process in order to design products that are easy to operate, and most importantly, help support correct and safe use.

Growing up with life-threatening allergies The idea for AUVI-Q Explore AUVI-Q from the inside out

Get your staff up to speed on AUVI-Q.

Nurses are often on the front lines of educating patients on the proper use of their AUVI-Q epinephrine auto‑injectors. Download and share this kit with your team so you have the resources needed to support your patients.

Download the kit

Indication

AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

Important Safety Information

AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.